Lecanemab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 691 publications
Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges.
Journal: The Senior care pharmacist
Published: April 12, 2026
Correction to "Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: A multicenter real-world study".
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: April 08, 2026
Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.
Journal: Journal of Alzheimer's disease : JAD
Published: April 03, 2026
Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.
Journal: Journal of managed care & specialty pharmacy
Published: March 26, 2026
Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
Comparison table: Drugs for Alzheimer's disease dementia.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy.
Journal: Journal of Alzheimer's disease : JAD
Published: March 20, 2026
Lecanemab alters basement membrane collagen IV in viable microvessels isolated from brains with high Alzheimer's disease neuropathology.
Journal: Journal of Alzheimer's disease : JAD
Published: March 20, 2026
Alzheimer's drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal.
Journal: BMJ (Clinical research ed.)
Published: March 20, 2026
Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review.
Journal: Journal of Alzheimer's disease : JAD
Published: March 16, 2026
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].
Journal: The journal of prevention of Alzheimer's disease
Published: March 14, 2026
Last Updated: 04/28/2026